<DOC>
	<DOC>NCT01677767</DOC>
	<brief_summary>This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible patients will be followed for 24 weeks.</brief_summary>
	<brief_title>An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patients, 18 to 65 years of age, inclusive Patients with chronic kidney disease on dialysis ESA na√Øve with Hb &lt; 10 g/dL, or on treatment with ESAs other than Mircera and Hb within the target range of 1012 g/dL Adequate irons status as judged by the treating physician Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication Clinically significant concomitant disease or disorder as defined by protocol Clinical suspicion of pure red cell aplasia (PRCA) Planned elective surgery during the study period , except for cataract surgery or vascular access surgery Transfusion of red blood cells in the previous 2 months Pregnant women Contraindications for Mircera according to local prescribing information or as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>